VivoSeq
Psychiatry

Depressive Episodes

0

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Depressive Episodes is an early-stage landscape with 0 programs across 3 companies. The most active players are AbbVie, Bayer, Xenon Pharmaceuticals Inc..

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AbbVie logo

AbbVie

0 programs

PreclinicalBayer logo

Bayer

0 programs

PreclinicalX

Xenon Pharmaceuticals Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

3

clinical trials

Recruiting2 · 67%
Completed1 · 33%

Clinical Trials

Trial Activity

Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder
Recruiting·AbbVie logoAbbVie·Phase 2·NCT07220460·200 enrolled
Study to Learn About Relapse Prevention of Hypericumextract (a Drug Based on the Plant St. John Wort) in Outpatients Suffering From Moderate Depressive Episodes
Completed·Bayer logoBayer·Phase 3·NCT04315597·398 enrolled
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
Recruiting·XXenon Pharmaceuticals Inc.·Phase 3·NCT07172516·400 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)